
**A REVIEW ON THE CULTIVATION, COLLECTION AND
PROCESSING OF DIGITALIS PURPUREA**

BM Khadeejath Riswana*, Nabeesath Saniya Sherein K. M.

Malik Deenar College of Pharmacy, Seethangoli, Bela P.O, Kasaragod, Kerala 671321.

Article Received: 12 April 2026, Article Revised: 02 May 2026, Published on: 22 May 2026***Corresponding Author: BM Khadeejath Riswana**

Malik Deenar College of Pharmacy, Seethangoli, Bela P.O, Kasaragod, Kerala 671321.

DOI: <https://doi-doi.org/101555/ijarp.4379>**ABSTRACT:**

Digitalis purpurea (Family: Scrophulariaceae), popularly known as foxglove, is a biennial herb native to Europe and widely cultivated across temperate regions for its ornamental and medicinal value. The leaves of the plant are rich in potent cardiac glycosides, primarily digoxin and digitoxin, which exert profound effects on cardiac function. However, these compounds possess a narrow therapeutic index, and unprocessed crude drug material can cause severe toxicity, including arrhythmias and systemic disturbances. Consequently, the raw drug must undergo careful processing involving controlled collection, drying, powdering, and extraction, followed by strict standardization using High-Performance Thin-Layer Chromatography (HPTLC) and Gas Chromatography-Mass Spectrometry (GC-MS) to ensure safety and efficacy. Chemically, the plant contains glycosides, flavonoids, phenolic compounds, and sterols, which contribute to its diverse pharmacological profile. Once properly standardized, *Digitalis purpurea* exhibits profound therapeutic applications, including cardiotonic, anti-inflammatory, and emerging anticancer properties, alongside limited industrial uses such as ornamental horticulture. This article reviews the botanical source, cultivation, safety requirements, pharmaceutical processing, and diverse applications of this highly potent yet dual-natured crude drug.

INTRODUCTION:

Digitalis purpurea commonly known as foxglove, is an important medicinal plant belonging to the family Scrophulariaceae. It is a biennial herb native to Europe and widely cultivated in temperate regions for both ornamental and therapeutic purposes. The plant produces tall

flowering spikes with purple, bell-shaped blossoms, and its leaves serve as the primary source of medicinal compounds.

The foliage is rich in **cardiac glycosides** such as digoxin and digitoxin, which exert profound effects on cardiac function. These compounds, however, are highly potent and can cause severe toxicity, including arrhythmias and systemic disturbances, if consumed in unprocessed form. Due to this narrow therapeutic margin, the crude drug is never used directly. After proper **processing**—which involves controlled collection, drying, powdering, and extraction—the plant becomes a cornerstone of modern medicine, particularly in the management of **congestive heart failure** and **atrial fibrillation**. Chemically, *Digitalis purpurea* also contains flavonoids, phenolic compounds, and sterols, which contribute to its broader pharmacological profile.

Thus, while raw foxglove material is dangerous, once carefully standardized, it holds immense therapeutic value and continues to be a vital pharmacognostic resource bridging traditional herbal knowledge with modern pharmacology.



FIG.NO.1: DIGITALIS PURPUREA.

➤ **BIOLOGICAL SOURCE:** it consist of dried leaves of *digitalis purpurea* belongs to the family *scrophularaceae*.

➤ **CHEMICAL CONSTITUENTS:**

1. Cardiac Glycosides (Primary Active Compounds):

- Digitoxin – Long-acting glycoside, highly lipophilic, accumulates in tissues.
- Digoxin – Shorter half-life, widely used in modern cardiology.
- Gitoxin – Similar pharmacological profile, less commonly used.
- Gitalin – Another glycoside with cardiac activity.
- Digitoxigenin and Digoxigenin

2. Flavonoids & Phenolic Compounds:

- Apigenin
- Luteolin
- Kaempferide
- Rosmarinic acid

3. Sterols & Terpenoids:

- Stigmasterol
- Campesterol
- Beta-amyrin




FIG.NO. 2: Chemical structure of digoxin.

CULTIVATION AND COLLECTION:

CULTIVATION:

Digitalis purpurea, commonly known as foxglove, is cultivated mainly in cool, temperate climates where the temperature ranges between 20–30 °C and at elevations of 1200–1800 m above sea level. The plant prefers well-drained sandy soil rich in organic matter with a pH of 5.5–6.5, as poor drainage can severely affect its growth. Propagation is usually done through seeds, which may be sown directly or raised in nurseries before transplanting. Seedlings are transplanted after 40–45 days, with spacing of about 45 cm between rows and 30 cm between plants to ensure proper growth. Fertilization involves the application of farmyard manure along with nitrogen and phosphorus, though organic manures like vermicompost are increasingly favored for improving soil health and enhancing leaf yield. During the first year, the crop produces 2–3 harvests of leaves, while in the second year, 2 harvests are taken along

with seed production. Leaves are plucked just before flowering, dried at controlled temperatures (around 60 °C with hot air circulation), and stored in airtight containers to preserve their glycoside content. On average, 2–5.5 tonnes of dried leaves per hectare can be obtained under proper cultivation practices.

COLLECTION:

The collection of *Digitalis purpurea*, or foxglove, focuses primarily on its leaves, which are the main source of valuable cardiac glycosides such as digitoxin and digoxin. Harvesting is carefully timed just before the plant begins to flower, since this stage ensures the highest concentration of active compounds. Leaves measuring about 8–10 cm in length are plucked without petioles, and collection is usually carried out two to three times during the first year and twice in the second year, when seed production also occurs. After harvesting, the leaves are dried at controlled temperatures around 60 °C using hot air circulation, with occasional stirring to prevent clumping and ensure uniform drying. Proper drying is essential to preserve the potency of glycosides, as improper handling can lead to degradation. Once dried, the leaves are stored in airtight containers with dehydrating agents such as silica gel to maintain their medicinal quality. Under good cultivation and collection practices, yields of 2–5.5 tonnes of dried leaves per hectare can be achieved, making *Digitalis purpurea* a highly valuable medicinal crop.

PROCESSING TECHNIQUE OF DIGITALIS PURPUREA:

Processing of *Digitalis purpurea* is carried out to ensure that its powerful cardiac glycosides can be safely and effectively used in medicine. The fresh plant contains unstable compounds that degrade quickly, so processing is necessary for stabilization to preserve their therapeutic activity. It also allows for standardization, since the natural concentration of glycosides varies depending on soil, climate, and harvest time, and consistent dosage is critical in treating heart conditions. Another important reason is purification, which removes unwanted or toxic substances from the crude plant material, leaving only the active compounds.

➤ **Harvesting:** Mature leaves are collected when Glycoside content is at its peak, Avoid very young or overly old plants, Ensure healthy, disease-free plants. Collect leaves from the upper portion of the stem because Upper leaves contain the highest concentration of cardiac glycosides and Avoid damaged or discolored leaves Upper leaves contain the highest concentration of cardiac glycosides. □

➤ **Dry the Plant Material:** Drying stabilizes glycosides and prevents degradation. Spread leaves in thin layers under controlled temperature, Avoid direct sunlight to preserve active compounds. This plant material is dried in ways such as air drying, hot drying, freeze drying.

➤ **Perform Solvent Extraction:** Extract crude glycosides using ethanol, methanol, or acetone solutions. Use maceration or Soxhlet extraction. Filter out plant debris. Evaporate excess solvent under reduced pressure. Store the glycoside rich solution in an airtight container in a dark and cool place.

➤ **Purify the Extract:** Purification ensures pharmaceutical-grade safety and consistency. The purification step of *Digitalis purpurea* is vital because the crude extract contains many unwanted plant compounds and impurities that could interfere with dosage accuracy or cause toxicity. Precipitation, Solvent Partitioning, Recrystallization.

i. Precipitation:

Remove unwanted compounds by selective precipitation. Add reagents that cause non-glycoside materials to precipitate, Filter out the solid impurities, Retain the liquid fraction containing glycosides.

ii. Solvent Partitioning:

Separate glycosides based on solubility in different solvents. Use solvents like chloroform or butanol, Transfer glycosides into the solvent phase, Discard aqueous phase with impurities.

iii. Recrystallization:

Obtain pure glycosides in crystalline form. Dissolve glycosides in a suitable solvent, Slowly cool to form crystals, Collect and dry crystals for pharmaceutical use.

iv. Quality Testing:

Ensure purity and potency of the final product. Perform chemical assays to confirm glycoside concentration, test for absence of toxic impurities, standardize dosage for medical applications.

v. Finalize Pharmaceutical Preparation:

Processed glycosides are formulated into medicines. Standardize dosage for clinical use. Package under strict regulatory compliance.

TOXIC PROFILE:

1. Dermal Hazard: Direct contact with the fresh leaves or sap may cause mild skin irritation or allergic reactions in sensitive individuals. Handling large quantities without protection can lead to redness, itching, or inflammation due to the presence of cardiac glycosides and other irritant compounds.

- 2. Systemic Toxicity:** Ingestion of unprocessed or excessive amounts of *Digitalis purpurea* can result in severe poisoning. Symptoms include nausea, vomiting, abdominal pain, visual disturbances (yellow or blurred vision), bradycardia, arrhythmias, and confusion. In extreme cases, cardiac arrest may occur due to inhibition of the Na^+/K^+ -ATPase enzyme, leading to elevated intracellular calcium levels.
- 3. Fatal Dose & Period:** The estimated fatal dose of digoxin or digitoxin is approximately **2–3 mg** for adults, depending on individual sensitivity. The fatal period may range from **6 to 24 hours** if untreated, with death typically resulting from ventricular fibrillation or cardiac standstill.

APPLICATIONS: □

- 1. Used to treat heart failure:** helps to strengthen heart contraction and regulate the heart rhythm. *Digitalis purpurea* is widely applied in the treatment of congestive heart failure because its cardiac glycosides, mainly digoxin and digitoxin, strengthen the contractions of the heart muscle and help regulate irregular rhythms. In patients with CHF, the heart struggles to pump blood effectively, leading to symptoms such as fatigue, shortness of breath, and fluid retention. By inhibiting the sodium-potassium ATPase pump, *Digitalis* increases intracellular calcium, which enhances the force of contraction and improves cardiac output. It also slows conduction through the atrioventricular node, making it useful in controlling atrial fibrillation often associated with CHF. □
- 2. Helps control arrhythmia:** increasing the vagal tone and inhibiting the AV node. *Digitalis purpurea* is also used in the management of arrhythmias, particularly atrial fibrillation and atrial flutter. Its cardiac glycosides, such as digoxin, act by slowing conduction through the atrioventricular (AV) node, which helps control the ventricular rate.
- 3. in patients with rapid atrial rhythms.** By increasing vagal tone, *Digitalis* reduces the number of impulses that pass from the atria to the ventricles, thereby stabilizing the heartbeat. This makes it especially useful in patients with atrial fibrillation who also have congestive heart failure, since it not only controls rhythm but also strengthens cardiac contractions. However, because of its narrow therapeutic window, careful monitoring is required to avoid toxicity, which can itself cause dangerous arrhythmias. In modern practice, *Digitalis* is often used as an adjunct therapy alongside beta-blockers or calcium channel blockers for rate control, rather than as the sole treatment. □

- 4. Used in medical and pharmacological research:** evaluate the therapeutic effects, biomarkers. *Digitalis purpurea* is not only important in clinical medicine but also widely used in medical and pharmacological research. Its cardiac glycosides, such as digoxin and digitoxin, serve as model compounds for studying the physiology of the heart, especially the mechanisms of contraction and rhythm regulation. Researchers use *Digitalis* to investigate how inhibition of the sodium-potassium ATPase pump affects intracellular calcium levels and cardiac output. In pharmacology, it is employed to understand drug receptor interactions, dose-response relationships, and the concept of a narrow therapeutic window, since even small variations in dosage can lead to toxicity. *Digitalis* also plays a role in developing new cardiac drugs, as its mechanism of action provides a foundation for designing safer and more effective therapies.
- 5. Important in studying drug toxicity and dose-response relationship:** *Digitalis purpurea* plays an important role in studying drug toxicity and drug response relationships because its cardiac glycosides, such as digoxin and digitoxin, have a very narrow therapeutic window. This means that the difference between a beneficial dose and a toxic dose is extremely small, making it an ideal model compound for pharmacological research. By examining how *Digitalis* affects the heart at different concentrations, researchers gain valuable insights into dose-response curves, receptor binding, and the mechanisms of drug action. It is also used to study drug interactions, since electrolyte imbalances or co-administration with diuretics can alter its effects and increase toxicity risk.
- 6. Used in quality control tests for cardiac glycosides:** *Digitalis purpurea* is also important in quality control tests for cardiac glycosides, ensuring that pharmaceutical preparations are safe, effective, and standardized. Because glycosides like digoxin and digitoxin have a very narrow therapeutic window, even small variations in concentration can lead to either reduced efficacy or dangerous toxicity. To prevent this, laboratories use chemical assays such as spectrophotometry, chromatography, and titration to measure the exact glycoside content in processed extracts. In addition, biological assays are performed using test animals or isolated tissues to confirm the pharmacological activity of the compounds. These tests help verify that each batch of *Digitalis*-derived medicine meets strict standards for potency and purity. By applying such quality control techniques, manufacturers ensure that patients receive consistent and reliable doses, minimizing risks while maximizing therapeutic benefits.

CONCLUSION:

Digitalis purpurea stands out as a remarkable pharmacological entity that seamlessly bridges classical herbal medicine with advanced pharmaceutical science. While the raw leaves contain potent cardiac glycosides capable of inducing serious systemic toxicity, modern extraction and purification techniques ensure safe therapeutic use. Through controlled solvent extraction and precise chromatographic separation, the active glycosides—digoxin and digitoxin—are isolated from non-polar impurities and standardized for clinical application.

Stringent pharmacopoeial standardization, including physical parameters (ash value, moisture content) and advanced analytical profiling via HPTLC and GC-MS, guarantees purity, potency, and structural authentication of the final product. When handled with proper safety protocols and dosage precision, *Digitalis purpurea* transforms from a potentially hazardous botanical into a life-saving therapeutic agent.

Ultimately, the purified extract delivers powerful cardiotoxic benefits for heart failure and arrhythmia management, while ongoing research explores its anti-inflammatory and anticancer potential. Thus, *Digitalis purpurea* exemplifies how meticulous pharmacognostic processing and modern analytical validation can convert a toxic natural source into a cornerstone of cardiovascular therapy and biomedical innovation.

REFERENCE:

1. Evans WC. Trease and Evans Pharmacognosy. 16th ed. London: Saunders Elsevier; 2009.
2. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. 55th ed. Pune: Nirali Prakashan; 2019.
3. Wallis TE. Textbook of Pharmacognosy. 5th ed. New Delhi: CBS Publishers; 2005.
4. Bruneton J. Pharmacognosy, Phytochemistry, Medicinal Plants. 2nd ed. Paris: Lavoisier Publishing; 1999.
5. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale's Pharmacology. 8th ed. London: Elsevier Churchill Livingstone; 2016.
6. Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill; 2011.